行情

NBRV

NBRV

Nabriva
NASDAQ

实时行情|Nasdaq Last Sale

0.5293
-0.0786
-12.93%
盘前: 0.5303 +0.001 +0.19% 08:17 04/03 EDT
开盘
0.5890
昨收
0.6079
最高
0.6070
最低
0.5202
成交量
255.44万
成交额
--
52周最高
3.190
52周最低
0.4975
市值
5,008.43万
市盈率(TTM)
-0.3910
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NBRV价格均价为3.833,最高价位7.00,最低价为1.000。

EPS

NBRV 新闻

更多
  • 全球抗疫:要么一荣俱荣,要么全盘皆输
  • 新浪财经 · 35分钟前
  • “50美分”交易员狂赚4亿美元后,将目标转向黄金
  • 新浪财经综合 · 1小时前
  • 当两个明斯基过程遭遇大幅冲击:美国企业面临大考
  • 新浪财经-自媒体综合 · 1小时前
  • 瑞幸“造假门”后:中介机构或连坐 被监管纳入核查
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

NBRV 简况

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
展开

微牛提供Nabriva Therapeutics PLC - ADR(NASDAQ-NBRV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NBRV股票新闻,以帮助您做出投资决策。